PCA3 messenger RNA species in benign and malignant prostate...

Details PCA3 messenger RNA species in benign and malignant prostate... PCA3 messenger RNA species in benign and malignant prostate...

2008-04-07

2010-02-02

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

07655408

ABSTRACT:
This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.

REFERENCES:
patent: 4581333 (1986-04-01), Kourilsky et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4786600 (1988-11-01), Kramer et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5002867 (1991-03-01), Macevicz
patent: 5068176 (1991-11-01), Vijg et al.
patent: 5112736 (1992-05-01), Caldwell et al.
patent: 5118801 (1992-06-01), Lizardi
patent: 5149625 (1992-09-01), Church et al.
patent: 5202231 (1993-04-01), Drmanac et al.
patent: 5219989 (1993-06-01), Sonenberg et al.
patent: 5283174 (1994-02-01), Arnold, Jr. et al.
patent: 5312728 (1994-05-01), Lizardi et al.
patent: 5399491 (1995-03-01), Kaclan et al.
patent: 5422252 (1995-06-01), Walker et al.
patent: 5466590 (1995-11-01), Sariaslani et al.
patent: 5503980 (1996-04-01), Cantor
patent: 5547842 (1996-08-01), Hogan et al.
patent: 5554516 (1996-09-01), Kaclan et al.
patent: 5585481 (1996-12-01), Arnold, Jr. et al.
patent: 5593974 (1997-01-01), Rosenberg et al.
patent: 5639604 (1997-06-01), Arnold, Jr. et al.
patent: 5656207 (1997-08-01), Woodhead et al.
patent: 5658737 (1997-08-01), Nelson et al.
patent: 5674682 (1997-10-01), Croce et al.
patent: 5773705 (1998-06-01), Vierstra et al.
patent: 5837832 (1998-11-01), Chee et al.
patent: 5861242 (1999-01-01), Chee et al.
patent: 5925517 (1999-07-01), Tyagi et al.
patent: 5939258 (1999-08-01), Croce et al.
patent: 6037130 (2000-03-01), Tyagi et al.
patent: 6087133 (2000-07-01), Dattagupta et al.
patent: 6110678 (2000-08-01), Weisburg et al.
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6280952 (2001-08-01), Weisburg et al.
patent: 6287820 (2001-09-01), Umansky et al.
patent: 6383739 (2002-05-01), Kurth et al.
patent: 6395278 (2002-05-01), Xu et al.
patent: 6465611 (2002-10-01), Xu et al.
patent: 6479263 (2002-11-01), Slawin et al.
patent: 6528260 (2003-03-01), Blumenfeld et al.
patent: 6534273 (2003-03-01), Weisburg et al.
patent: 6551778 (2003-04-01), Harvey et al.
patent: 6800746 (2004-10-01), Xu et al.
patent: 6897024 (2005-05-01), Bussemakers et al.
patent: 7008765 (2006-03-01), Bussemakers et al.
patent: 7138235 (2006-11-01), Bussemakers et al.
patent: 7368545 (2008-05-01), Busse et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0035244 (2002-03-01), Cohen et al.
patent: 2005/0158792 (2005-07-01), Bussemakers et al.
patent: 2005/0164223 (2005-07-01), Schalken et al.
patent: 2005/0282170 (2005-12-01), Fradet et al.
patent: 2006/0099658 (2006-05-01), Bussemakers et al.
patent: 0 160 228 (1985-11-01), None
patent: 0 320 308 (1989-06-01), None
patent: 0 520 794 (1992-12-01), None
patent: 0 747 706 (1996-12-01), None
patent: WO 93/08845 (1993-05-01), None
patent: WO 93/13121 (1993-07-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 94/15646 (1994-07-01), None
patent: WO 95/28498 (1995-10-01), None
patent: WO 95/32305 (1995-11-01), None
patent: WO96/11266 (1996-04-01), None
patent: WO 96/14875 (1996-05-01), None
patent: WO96/32966 (1996-10-01), None
patent: WO 98/02582 (1998-01-01), None
patent: WO 98/45420 (1998-10-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/50899 (2000-08-01), None
patent: WO 00/58470 (2000-10-01), None
patent: WO 01/23550 (2001-04-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/25273 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/44507 (2001-06-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 02/24718 (2002-03-01), None
patent: WO 02/30268 (2002-04-01), None
Altschul, S.F., at al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,”Nucl. Acids Res.25:3389-3402, Oxford University Press (1997).
Arnold, Jr., L.J., et al, “Assay Formats Involving Acridinium-Ester-Labe/ed DNA Probes,”Clin. Chem.35:1588-1594, American Association for Clinical Chemistry (1989).
Black, D.L., “Mechanisms of Alternative Pre-Messenger RNA Splicing,”Annu. Rev. Biochem.72:291-336 (Feb. 2003).
Boom, R., et al., “Rapid and Simple Method for Purification of Nucleic Acids,”J. Clin. Microbiol.28:495-503, American Society for Microbiology (1990).
Boulikas, T., “Gene Therapy of Prostate Cancer: p. 53, Suicidal Genes, and Other Targets,”Anticancer Res.17:1471-1505, International Institute of Anticancer Research (1997) .
Bowie, J.U., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1311, American Association for the Advancement of Science (1990).
Brakebusch, C., et al., “Expression of the 90K Immunostimulator Gene Is Controlled by a Promoter with Unique Features,”J. Biol. Chem.272:3674-3682, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Brown, A.M., “A step-by-step guide to non-linear regression analysis of experimental data using a Microsoft Excel spreadsheet,”Comput. Methods Programs Biomed.65:191-200, Elsevier Scientific Publishers (Jun. 2001).
Buck, G.A., et al., “Design Strategies and Performance of Custom DNA Sequencing Primers,”BioTechniques27:528-536, Informa Healthcare USA, Inc. (Sep. 1999).
Burgess, W.H., et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell. Biol.111 :2129-2138, The Rockefeller University Press (1990).
Bussemakers, M.J., and Isaacs, W.B., “Identification of Genes Associated with Prostate Cancer Development,”Urol Res.21:452, Abstract No. P42, Springer International (1993).
Bussemakers, M.J.G., and Isaacs, W.B “Identification of Genes Associated with Prostate Cancer Development,” Presented at8th Annual Spring Meeting, May 13 - May 14, San Fransico, CA, one page, Society for Basic Urologic Research (1994).
Bussemakers, M.J.G., et al., “Identification of DD3: A Now Gene Overexpressed in Prostatic Tumors,”Urol. Res.23:253, Abstract No. 0 36, Springer International (1995).
Bussemakers, M.J.G., et al, “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,” Presented atFall Symposium, Dec. 7-10, Chapel Hill, North Carolina, 1 page, Society for Basic Urologic Research (1995).
Bussemakers, M.J.G., et al., “DD3: a new prostate specific marker, overexpressed in prostatic tumors,”Proc. Annu. Meet. Amer. Assoc. Cancer Res.87:515, Abstract No, 3522, American Association for Cancer Research (1996) .
Bussemakers, M.J.G., et al., “DD3: a new prostate specific marker, overexpressed in prostatic tumors,”Presented at the 87thAnnual Meeting of the American Association for Cancer Research, Washington, DC, Abstract No. 3522, 1 page (1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,” Presented atBreast and Prostate Cancer: Basic Mechanisms, Taos, New Mexclo, Abstract No. 102, 1 page (Jan. 29 - Feb. 4 1996).
Bussemakers, M.J.G., et al., “DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors,” Presented atMeeting for the Dutch Association for Tumor Cell Biology, May, The Netherlands, 1 page (1996)
Bussemakers, M.J.G., et al., “DD3: A New Prostate-Specific Marker, St

Affiliated with

Also associated with

Rating

PCA3 messenger RNA species in benign and malignant prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PCA3 messenger RNA species in benign and malignant prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PCA3 messenger RNA species in benign and malignant prostate... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4176442